Healthcare provider profile · identity verified

Sarah J. Smith, MD

Family Practice · BROOKIGNS, SD · NPI 1538119581

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Losartan Potassium	Losartan Potassium	144	31
Levothyroxine Sodium	Levothyroxine Sodium	132	29
Metoprolol Succinate	Metoprolol Succinate	129	33
Atorvastatin Calcium	Atorvastatin Calcium	99	25
Lisinopril	Lisinopril	98	26
Metformin Hcl Er	Metformin Hcl	98	22
Gabapentin	Gabapentin	94	19
Bupropion Xl	Bupropion Hcl	81	suppressed
Trazodone Hcl	Trazodone Hcl	74	14
Omeprazole	Omeprazole	73	18
Rosuvastatin Calcium	Rosuvastatin Calcium	64	20
Sertraline Hcl	Sertraline Hcl	62	12
Hydrochlorothiazide	Hydrochlorothiazide	59	17
Furosemide	Furosemide	57	16
Alendronate Sodium	Alendronate Sodium	54	18
Amlodipine Besylate	Amlodipine Besylate	52	12
Duloxetine Hcl	Duloxetine Hcl	52	suppressed
Spironolactone	Spironolactone	52	17
Escitalopram Oxalate	Escitalopram Oxalate	51	suppressed
Tramadol Hcl	Tramadol Hcl	44	15
Simvastatin	Simvastatin	42	suppressed
Allopurinol	Allopurinol	40	12
Paroxetine Hcl	Paroxetine Hcl	40	suppressed
Carvedilol	Carvedilol	38	suppressed
Potassium Chloride	Potassium Chloride	37	suppressed
Warfarin Sodium	Warfarin Sodium	35	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	32	suppressed
Montelukast Sodium	Montelukast Sodium	32	suppressed
Prednisone	Prednisone	32	15
Glipizide Er	Glipizide	31	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	31	suppressed
Pregabalin	Pregabalin	31	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	30	12
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	30	suppressed
Ezetimibe	Ezetimibe	30	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	29	suppressed
Donepezil Hcl	Donepezil Hcl	28	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	28	suppressed
Lorazepam	Lorazepam	27	suppressed
Olanzapine	Olanzapine	27	suppressed
Carbamazepine	Carbamazepine	26	suppressed
Eliquis	Apixaban	26	suppressed
Lamotrigine	Lamotrigine	26	suppressed
Memantine Hcl	Memantine Hcl	24	suppressed
Metformin Hcl	Metformin Hcl	24	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	23	suppressed
Buspirone Hcl	Buspirone Hcl	21	suppressed
Fentanyl	Fentanyl	21	suppressed
Risperidone	Risperidone	21	suppressed
Trulicity	Dulaglutide	20	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	20	suppressed
Jardiance	Empagliflozin	19	suppressed
Fluticasone Propionate	Fluticasone Propionate	18	suppressed
Ibandronate Sodium	Ibandronate Sodium	17	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	16	suppressed
Cholestyramine Light	Cholestyramine	16	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	16	suppressed
Atenolol	Atenolol	15	suppressed
Estradiol	Estradiol	14	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Clopidogrel	Clopidogrel Bisulfate	13	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Modafinil	Modafinil	13	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	13	suppressed
Raloxifene Hcl	Raloxifene Hcl	13	suppressed
Synthroid	Levothyroxine Sodium	13	suppressed
Telmisartan	Telmisartan	13	suppressed
Vraylar	Cariprazine Hcl	13	suppressed
Xarelto	Rivaroxaban	13	suppressed
Clonazepam	Clonazepam	12	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	12	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	12	suppressed
Alprazolam	Alprazolam	11	suppressed
Glimepiride	Glimepiride	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed
Oxycodone Hcl	Oxycodone Hcl	11	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	11	suppressed
Terazosin Hcl	Terazosin Hcl	11	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error